Ascletis Pharma, Inc. (HK:1672) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Ascletis Pharma Inc. has announced that its subsidiary Gannex’s strategic partner, Sagimet Biosciences, received FDA Breakthrough Therapy designation for the drug ASC40, aimed at treating a serious liver condition known as MASH. This status could expedite ASC40’s development process, as it has shown substantial improvement over existing treatments in clinical trials. Investors are advised, however, that there is no guarantee of successful development or commercialization of the drug.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.